Analytical Data
-
Gene name
IFNa10
- Application
-
Alternative Names
IFNa10；Interferon alpha-10
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01566
-
Expression Region
24-189aa
-
AA Sequence
CDLPQTHSLGNRRALILLGQMGRISPFSCLKDRHDFRIPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTEDSSAAWEQSLLEKFSTELYQQLNDLEACVIQEVGVEETPLMNEDSILAVRKYFQRITLYLIERKYSPCAWEVVRAEIMRSLSFSTNLQKRLRRKD
-
Molecular Weight
21.4kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interferon alpha 10 (IFNa10) is a member of the interferon family, which plays a crucial role in the immune response against viral infections and other pathogens. It is primarily produced by plasmacytoid dendritic cells and is known for its antiviral, antiproliferative, and immunomodulatory effects. Research into IFNa10 has gained momentum due to its potential therapeutic applications in various medical conditions, including viral hepatitis, specific cancers, and autoimmune diseases. IFNa10 exhibits a distinct signaling pathway compared to other interferons, leading to unique biological activities, which makes it a target of interest for drug development. The recombinant production of IFNa10 has enabled scientists to study its functions in detail and explore its efficacy in clinical settings. Moreover, the use of recombinant proteins allows for controlled experiments and the possibility of enhancing its therapeutic properties through genetic engineering. Given the increasing prevalence of viral infections and the limitations of existing treatments, understanding the mechanisms of action of IFNa10 and its potential as a therapeutic agent is of significant importance in the field of immunology and infectious diseases. As research progresses, IFNa10's role in modulating immune responses offers promising avenues for developing novel treatment strategies.
